Cognos Therapeutics adds Innovobot executive to advisory board

Cognos Therapeutics named Innovobot US Labs Senior Executive Miguel Adao to its Industry Advisory Board as the company pushes forward on FDA preparation for SINNAIS, its AI-driven implantable drug delivery platform. The move is meant to strengthen commercialization, engineering and market-readiness efforts as Cognos also works toward a future Nasdaq listing.

Why it matters: - Cognos Therapeutics is building toward commercializing SINNAIS, a fully implantable AI-powered drug delivery platform aimed at Alzheimer’s and other neurodegenerative diseases. - The company is also advancing FDA regulatory preparation and laying groundwork for a future Nasdaq listing. - Adding a senior executive with cross-industry operating experience could support Cognos’ push from development to commercialization.

What happened: - Cognos Therapeutics appointed Dr. Miguel Adao, a Senior Executive at Innovobot US Labs Corporation, to its Industry Advisory Board effective immediately. - The announcement was made July 6, 2026, in Inglewood, California. - Cognos said the appointment comes as the company advances FDA regulatory preparation and works toward a future Nasdaq listing.

The details: - Dr. Adao previously served as President and CEO of Voler Systems, a Silicon Valley company focused on electronic design for medical devices, wearables and IoT devices. - Voler Systems has been acquired by Innovobot Inc. - Cognos said Dr. Adao helped deliver the best three years in Voler’s 47-year history. - His prior leadership roles include positions at Hewlett-Packard, VMware, Cigna Healthcare, Procter & Gamble and PepsiCo. - Dr. Adao holds a Doctorate in Business Administration from the International School of Management in Paris, an MBA in International Business from Ohio University and a bachelor’s degree in computer engineering from the Florida Institute of Technology. - He has lived and worked in eight countries and is fluent in five languages. - Dr. Adao has also served on multiple advisory boards. - Innovobot US Labs, operating under the Voler Systems name after the acquisition, has been commissioned to lead engineering work for a commercial-grade version of SINNAIS. - SINNAIS is designed to monitor biomarkers in cerebrospinal fluid, including beta-amyloid and tau proteins, and deliver precise doses of FDA-approved drugs directly to the brain. - Cognos says the platform is intended to bypass the blood-brain barrier, improve drug efficacy, reduce systemic side effects and potentially slow or halt Alzheimer’s progression. - Cognos compares the device’s intended role in Alzheimer’s care to an implantable defibrillator in cardiology. - Cognos said Dr. Adao’s industry relationships, commercialization expertise and executive leadership strengthen its readiness to bring SINNAIS to market. - The company also said the appointment strengthens alignment between Cognos and Innovobot, whose partner network is helping drive pre-commercial and regulatory strategy for SINNAIS.

Between the lines: - The board appointment signals that Cognos is trying to add operating and commercialization experience at a time when technical development alone is not enough. - The Innovobot link also suggests Cognos is leaning on outside expertise for both engineering execution and market strategy. - The company is positioning SINNAIS as a potentially category-defining device, but the language remains forward-looking and tied to regulatory and clinical milestones that still lie ahead.

What’s next: - Cognos will continue pursuing FDA regulatory processes for SINNAIS. - Innovobot US Labs is expected to keep working on engineering for the commercial-grade version of the platform. - Cognos says it still aims for a future Nasdaq listing, though no timetable was given. - The company’s investor relations and media contact emails remain ir@cognosthx.com and media@cognosthx.com.

The bottom line: - Cognos is adding a seasoned operator to its advisory board as it tries to move SINNAIS from ambitious neurotech concept to regulated, market-ready product.